CN115715289A - 多芳基化合物及应用 - Google Patents

多芳基化合物及应用 Download PDF

Info

Publication number
CN115715289A
CN115715289A CN202180039658.1A CN202180039658A CN115715289A CN 115715289 A CN115715289 A CN 115715289A CN 202180039658 A CN202180039658 A CN 202180039658A CN 115715289 A CN115715289 A CN 115715289A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
optionally substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039658.1A
Other languages
English (en)
Inventor
刘磊
刘扬
周峰
张国宝
唐任宏
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of CN115715289A publication Critical patent/CN115715289A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了式(I)所示的新型多芳基化合物或其药学可接受的盐，含有它们的药物组合物以及作为EGFR激酶抑制剂在预防或治疗相关疾病中的用途。
Figure DDA0003976260120000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180039658.1A 2020-06-03 2021-06-01 多芳基化合物及应用 Pending CN115715289A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010495249 2020-06-03
CN202010495249X 2020-06-03
PCT/CN2021/097574 WO2021244502A1 (zh) 2020-06-03 2021-06-01 多芳基化合物及应用

Publications (1)

Publication Number Publication Date
CN115715289A true CN115715289A (zh) 2023-02-24

Family

ID=78830655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039658.1A Pending CN115715289A (zh) 2020-06-03 2021-06-01 多芳基化合物及应用

Country Status (2)

Country Link
CN (1) CN115715289A (zh)
WO (1) WO2021244502A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4129996A4 (en) * 2020-03-23 2023-07-12 Qilu Pharmaceutical Co., Ltd. NEW EGFR AMINOPYRIMIDINE INHIBITOR

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601573A (zh) * 2014-11-24 2016-05-25 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
CN106831730A (zh) * 2017-01-11 2017-06-13 温州医科大学 一种取代的二氨基嘧啶类化合物及其在制备抗恶性肿瘤药物中的用途
WO2019015655A1 (zh) * 2017-07-19 2019-01-24 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020200191A1 (en) * 2019-04-04 2020-10-08 Betta Pharmaceuticals Co., Ltd Egfr inhibitors, compositions and methods there of
WO2020216371A1 (zh) * 2019-04-26 2020-10-29 江苏先声药业有限公司 Egfr抑制剂及其应用
WO2020253860A1 (zh) * 2019-06-21 2020-12-24 江苏豪森药业集团有限公司 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN114430739A (zh) * 2019-07-26 2022-05-03 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
CN112538072B (zh) * 2019-09-21 2024-02-06 齐鲁制药有限公司 氨基嘧啶类egfr抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601573A (zh) * 2014-11-24 2016-05-25 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
CN106831730A (zh) * 2017-01-11 2017-06-13 温州医科大学 一种取代的二氨基嘧啶类化合物及其在制备抗恶性肿瘤药物中的用途
WO2019015655A1 (zh) * 2017-07-19 2019-01-24 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物

Also Published As

Publication number Publication date
WO2021244502A1 (zh) 2021-12-09

Similar Documents

Publication Publication Date Title
CN113166103B (zh) Egfr抑制剂及其应用
CN107873032B (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN107995911B (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
TW202115042A (zh) 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
WO2021245055A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20220047329A (ko) 키나제 억제제로서의 헤테로시클릭 화합물
JP2023504113A (ja) 置換三環式化合物
CN113801114A (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
US20230113478A1 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
CN117062818A (zh) 新型sos1抑制剂及其制备方法和应用
WO2023099612A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114728932A (zh) 作为egfr激酶抑制剂的多芳基化合物
CN115715289A (zh) 多芳基化合物及应用
CN114685489A (zh) 多取代含氮杂环类化合物及其应用
CN108329274B (zh) 布鲁顿酪氨酸激酶抑制剂
CN113773262A (zh) 哒嗪类化合物
CN113735836A (zh) 哒嗪类化合物及其应用
CN115023428A (zh) 嘧啶并吡咯类化合物
CN108779100B (zh) 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
AU2018301837A1 (en) Tam kinase inhibitors
TW202311252A (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
CN114874234A (zh) 作为kras g12c抑制剂的三环类化合物及其应用
CN116783178A (zh) 含联环的tyk2抑制剂化合物
CN114805438A (zh) 含磷酰基的tyk2抑制剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination